Medipattern Receives U.S. Patent for Multi-Modality Detection of Lesions Furthering Its Technology
CADENZA(TM) Algorithm Platform Receives Extended Patent Protection for Kinetic Studies and Combining Imaging Techniques
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 11/03/11 -- Attention: Business/Financial Editors
The Medipattern Corporation ("Medipattern") (TSX VENTURE: MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, is pleased to announced that it received United States Patent number 8,014,576 for a "method and system of computer-aided quantitative and qualitative analysis of medical images." The patent relates to the field of computer-aided analysis of medical images and detection of suspicious abnormalities. It defines a method and system for processing medical images obtained from multiple modalities, including analysis of kinetics as well as morphological features and automated detection of abnormalities, and analysis of medical images from multiple modalities.
The patent extends the core technology for Medipattern embodied in its Cadenza™ Platform to analyze and characterize medical images. Medipattern's previous patent, number 7,783,094, addressed computer aided detection in medical images which are analyzed, to extract and identify a set of features in the image relevant to a diagnosis. This new patent also covers the combined use of morphological and kinetic features to compute a consolidated assessment of a possible lesion detected in medical imaging. Though the technology was primarily invented for the use of combining the various image modalities in breast imaging (x-ray based mammography, Ultrasound, Computed Tomography (CT), Positron Emission Tomography (PET/CT), Magnetic Resonance Imaging (MRI), MR Spectroscopy (MRS) and Nuclear Imaging, the patented algorithm can be used in other medical imaging applications where the combination of various modalities can lead to a better understanding of the abnormality as would be the case for vascular imaging studies that use US, CT Angiography and MR Angiography to diagnose patients. The inventors are Jeffrey Collins, President and CEO of Medipattern, Frederic Lachmann, Ph. D, Chief Technology Officer of Medipattern, Karen Saghatelyan, and Sandra Stapleton. The technology is under review for patent protection in several other countries globally.
"The new patent solidifies Medipattern's position as a globally recognized leading edge developer of medical imaging analysis tools. We congratulate the entire team at Medipattern for their accomplishment and their contribution to the furtherance of medical science," commented Janet Sterritt, VP of Business Strategy for Medipattern. "Cadenza is the basis for our B-CAD®, B-CADmri™ and Visualize:Vascular™ products. B-CADmri technology was subsequently exclusively licensed to Sentinelle Medical, now a Hologic company. The combined capabilities of detection, identification, characterization, rendering and visualization form a medical image analysis tool set that is unique to Medipattern. The combination of being able to identify the lesion in pictures, characterize it in words, measure it analytically and assess its level is highly valued in being able to fully assist physicians in more readily assessing the extent of lesions. Medipattern also adds 3D rendering with our new vascular product line so that the physician can visualize critical anatomy, providing a new perspective."
About The Medipattern Corporation:
Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza™ technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website: .
Medipattern® is a registered mark of The Medipattern Corporation. Visualize:Vascular™ is a trademark of the Medipattern Corporation.
Forward-looking statements
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings (posted at ). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
The Medipattern Corporation
Jeff Collins
CEO
(416) 744-0009 ext. 224
Spinnaker Capital Markets Inc.
Kevin O'Connor
(416) 962-3300 ext. 226
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2011 - 11:00 Uhr
Sprache: Deutsch
News-ID 83494
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Software
Diese Pressemitteilung wurde bisher 379 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medipattern Receives U.S. Patent for Multi-Modality Detection of Lesions Furthering Its Technology"
steht unter der journalistisch-redaktionellen Verantwortung von
The Medipattern Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
